Scailyte CHU Rennes announce Covid-19 partnership. Scailyte AG, a Swiss startup in the emerging and rapidly growing field of single-cell technologies, raised CHF 3.1 million in a pre-Series A round led by Swisscom Ventures.
The ScaiVision™ biomarker discovery platform delivers best-in-class performance for supervised
pattern recognition analysis of single-cell data. The performance and clinically-relevant application of the core deep learning algorithm of ScaiVision have been validated in several scientific papers and
have resulted in patent-pending diagnostic applications. For more information visit www.scailyte.com
Scailyte™ and ScaiVision™ are registered trademarks proprietary to Scailyte AG.
Recent News
Transforming Healthcare with Unmatched Biomarker Discovery Power
Experience the game-changing convergence of AI and healthcare. Join us on this journey as we transla...
Recent News
LSX Congress USA 2023
Join Scailyte at the LSX Congress USA in Boston on September 13-14 at the Hynes Convention Centre, B...
Recent News
Unveiling ScaiVision's Clinical Potential
Embarking on the last leg of our Discovery Potential series, we're delving into ScaiVision's incredi...
Recent News
ScaiDigest Volume 3: Unveiling Immuno-Oncology's Next Frontier
In Volume 3, our very own Diana Stoycheva takes the helm to explore the fascinating realm of single-...
Recent News
Revolutionizing Biomarker Discovery: Unlock the Power of Scailyte's AI platform
Dive into the forefront of scientific advancement with Scailyte's groundbreaking AI platform, ScaiVi...
Recent News
Empowering Precision Healthcare with Unparalleled Discovery Potential
From revealing hidden insights to transforming healthcare, ScaiVision is rewriting the rules of disc...
Recent News
Accelerating Discoveries with Scailyte's Speed Strength
In the world of clinical research and development, time is of the essence. Our mission at Scailyte i...
Recent News
Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth
At Scailyte, our commitment to ESG goes beyond numbers. It extends to every individual within our vi...
Recent News
Transforming Healthcare with Unmatched Biomarker Discovery Power
Experience the game-changing convergence of AI and healthcare. Join us on this journey as we transla...
LSX Congress USA 2023
Join Scailyte at the LSX Congress USA in Boston on September 13-14 at the Hynes Convention Centre, B...
Recent News
Unveiling ScaiVision's Clinical Potential
Embarking on the last leg of our Discovery Potential series, we're delving into ScaiVision's incredi...
ScaiDigest Volume 3: Unveiling Immuno-Oncology's Next Frontier
In Volume 3, our very own Diana Stoycheva takes the helm to explore the fascinating realm of single-...
Recent News
Revolutionizing Biomarker Discovery: Unlock the Power of Scailyte's AI platform
Dive into the forefront of scientific advancement with Scailyte's groundbreaking AI platform, ScaiVi...
Empowering Precision Healthcare with Unparalleled Discovery Potential
From revealing hidden insights to transforming healthcare, ScaiVision is rewriting the rules of disc...
Recent News
Accelerating Discoveries with Scailyte's Speed Strength
In the world of clinical research and development, time is of the essence. Our mission at Scailyte i...
Nurturing Wellbeing in Our Workspace: Prioritizing People's Growth
At Scailyte, our commitment to ESG goes beyond numbers. It extends to every individual within our vi...